Carregant...
Evaluation and reflection on claudin 18.2 targeting therapy in advanced gastric cancer
Claudin 18.2 (CLDN18.2) is a tight-junction protein. CLDN18.2-targeting strategy has cut a striking figure in CLDN18.2 positive patients with advanced gastric cancer. Zolbetuximab, the CLDN18.2 antibody, obtained a better clinical benefit in patients compared with the controlled. In phase II trials,...
Guardat en:
| Publicat a: | Chin J Cancer Res |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
AME Publishing Company
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7219097/ https://ncbi.nlm.nih.gov/pubmed/32410803 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21147/j.issn.1000-9604.2020.02.13 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|